Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Marketing Ability Could Become Decisive Factor as All DPP-4 Inhibitors Are Likely to Obtain the Same Concurrent-use Indications
February 4, 2013
- Daiichi Sankyo Sees 7.1% Sales Rise in April-December, Cuts Domestic Forecast for Nexium
February 1, 2013
- Chugai Begins Development of Hyperlipidemia Antibody RG7652
February 1, 2013
- Oncology Products Boost Sales, Profits in 2012, but Both Fall Short of Midterm Targets: Chugai
February 1, 2013
- Chugai’s New Midterm Plan Includes No Sales or Profit Targets, Aims for Increased Marketing Productivity
February 1, 2013
- BindRen Approved in Europe for Hyperphosphatemia: MTPC
January 31, 2013
- Chugai Files NDA for Antibody-Drug Conjugate T-DM1 for HER2-Positive Breast Cancer
January 31, 2013
- Higher Dose of Toviaz Further Reduces Urge Urinary Incontinence in Patients with OAB: Pfizer
January 31, 2013
- TS-1 Superior to Gemcitabine in Extending OS of Resected Pancreatic Cancer Patients in PIII Study: Taiho
January 30, 2013
- No New Safety Concerns Found in All-Case PMS of Vectibix: Takeda
January 30, 2013
- “Hybrid” Bioventures Might Help Japanese Pharmas Compete in the Global Market: Prof. Kneller
January 30, 2013
- Number of MR-Qualified MSs Reaches 840 with 376 Newly Passing MR Exam: Medipal Group
January 30, 2013
- Nesina Approved in US: Takeda
January 29, 2013
- Medipal Group Introduces Special Mini Cooler for New Orphan Drug
January 29, 2013
- Kyowa Kirin to Apply for KRN125 in 2013
January 28, 2013
- Ono, DSP Cancel Development of Limaprost for CTS
January 28, 2013
- Novartis AG: Annual Sales Down, Profits Up, Gilenya Reaches Blockbuster Status
January 28, 2013
- Market for Novel Oral Anticoagulants to Heat Up as More Companies Compete for Low-risk Patients
January 28, 2013
- Otsuka to Hire 55 Grads of 6-Year Pharmaceutical Universities as MRs in FY2013: Jiho Poll
January 25, 2013
- Novartis, Sanofi Dissolve Partnership on Equa Copromotion
January 25, 2013
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…